Literature DB >> 18317760

Response to taxanes in triple negative breast cancer.

Nilufer Bulut, Sadettin Kilickap, Ebru Sari, Kadri Altundag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18317760     DOI： 10.1007/s00280-008-0717-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  4 in total

1.  Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.

Authors:  Anna Diana; Elisena Franzese; Sara Centonze; Francesca Carlino; Carminia Maria Della Corte; Jole Ventriglia; Angelica Petrillo; Ferdinando De Vita; Roberto Alfano; Fortunato Ciardiello; Michele Orditura
Journal:  Curr Oncol Rep       Date:  2018-08-20       Impact factor: 5.075

2.  Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity.

Authors:  Yuan Chun Ding; Linda Steele; Charles Warden; Sharon Wilczynski; Joanne Mortimer; Yuan Yuan; Susan L Neuhausen
Journal:  Oncotarget       Date:  2019-01-04

3.  Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer.

Authors:  Michael W Lewis; Kamila Wisniewska; Caitlin M King; Shen Li; Alisha Coffey; Michael R Kelly; Matthew J Regner; Hector L Franco
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.575

4.  Prognostic value of long non-coding RNAs in triple negative breast cancer: A PRISMA-compliant meta-analysis.

Authors:  Shuo Zhang; Feixia Ma; Xiaohong Xie; Yong Shen
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.